La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Vera Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Vera Therapeutics ha un patrimonio netto totale di $327.9M e un debito totale di $50.3M, che porta il suo rapporto debito/patrimonio netto a 15.3%. Le sue attività totali e le sue passività totali sono rispettivamente $397.3M e $69.4M.

Informazioni chiave

15.3%

Rapporto debito/patrimonio netto

US$50.26m

Debito

Indice di copertura degli interessi	n/a
Contanti	US$384.39m
Patrimonio netto	US$327.87m
Totale passività	US$69.42m
Totale attività	US$397.29m

Aggiornamenti recenti sulla salute finanziaria

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Jul 05

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Recent updates

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Feb 16

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Jan 19

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

Jan 07

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Oct 25

Vera Therapeutics soars 16% on three new favorable view from analysts

Jun 08

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( $394.7M ) di VERA superano le sue passività a breve termine ( $18.4M ).

Passività a lungo termine: Le attività a breve termine di VERA ( $394.7M ) superano le sue passività a lungo termine ( $51.0M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: VERA ha più liquidità del suo debito totale.

Riduzione del debito: Dati insufficienti per determinare se il rapporto debito/patrimonio netto di VERA si sia ridotto negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: VERA ha una cash runway sufficiente per più di 3 anni in base al suo attuale free cash flow.

Previsione Cash Runway: VERA ha una liquidità sufficiente per 2 anni se il flusso di cassa libero continua a ridursi ai tassi storici del 36.5 % ogni anno.

Vera Therapeutics Salute del bilancio

Salute finanziaria criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Recent updates

Vera Therapeutics' Atacicept: A Potential Game-Changer In IgA Nephropathy

Is Vera Therapeutics (NASDAQ:VERA) Using Debt In A Risky Way?

Vera Therapeutics, Inc.(NasdaqGM:VERA) dropped from Russell 3000E Value Index

Vera Therapeutics, Inc. Announces Appointment of David L. Johnson as Chief Operating Officer

Vera Therapeutics, Inc. Appoints Christy Oliger to the Board

Vera Therapeutics, Inc. Presents 72-Week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

Insider exercised options and sold US$1.0m worth of stock

Insider recently sold US$229k worth of stock

Price target increased by 17% to US$55.80

Chief Financial Officer recently sold US$735k worth of stock

Chief Financial Officer notifies of intention to sell stock

Vera Therapeutics, Inc., Annual General Meeting, May 15, 2024

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $250.000027 million.

Vera Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $200 million.

Price target increased by 36% to US$32.11

New minor risk - Share price stability

Vera Therapeutics: Soaring On IgAN Data, But Full Approval A Distant Prospect

Vera Therapeutics, Inc. Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b Origin Clinical Trial Ole in IgA Nephropathy

Vera Therapeutics, Inc. Announces Executive Changes

New minor risk - Share price stability

Price target increased by 12% to US$22.14

New major risk - Revenue and earnings growth

Price target increased by 16% to US$18.50

Price target increased by 10% to US$16.00

Price target decreased by 10% to US$14.50

New minor risk - Share price stability

Vera Therapeutics Appoints Kerry Cooper, M.D., as Senior Vice President of Medical Affairs

Price target decreased by 18% to US$15.67

Chief Financial Officer recently bought US$100k worth of stock

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $100.000005 million.

Vera Therapeutics, Inc. Releases 36 Week Interim Analysis of Phase 2b Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Vera Therapeutics, Inc. Hosting A Key Opinion Leader Webinar on Atacicept for the Treatment Iga Nephropathy (Igan)

Price target decreased to US$19.17

Vera Therapeutics, Inc. Announces Positive Topline Results of Phase 2b ORIGIN Clinical Trial of Atacicept for the Treatment of IgA Nephropathy

Chief Development Officer exercised options and sold US$148k worth of stock

Founder exercised options to buy US$1.1m worth of stock.

High number of new directors

Chief Development Officer exercised options and sold US$95k worth of stock

Founder exercised options and sold US$576k worth of stock

Chief Development Officer exercised options and sold US$186k worth of stock

Founder exercised options and sold US$622k worth of stock

Vera Therapeutics: Under The Radar IgAN Player Has Much To Prove

Founder exercised options and sold US$354k worth of stock

Vera Therapeutics GAAP EPS of -$0.55 beats by $0.17

Vera Therapeutics Completes Patient Enrollment in Phase 2B Origin Clinical Trial of Atacicept for the Treatment of Iga Nephropathy

Chief Financial Officer recently bought US$68k worth of stock

Vera Therapeutics, Inc. Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients

High number of new directors

Vera Therapeutics Announces Two Oral Presentations at the 59th European Renal Association – European Dialysis and Transplant Association Congress Featuring New Clinical Data on Atacicept in IgA Nephropathy and in Systemic Lupus Erythematosus

High number of new directors

Vera Therapeutics, Inc., Annual General Meeting, May 24, 2022

Vera Therapeutics Announces Appointment of Michael M. Morrissey, Ph.D., as Chairman of its Board of Directors

Companies Like Vera Therapeutics (NASDAQ:VERA) Are In A Position To Invest In Growth

Vera Therapeutics Announces Phase 3 Clinical Trial for Atacicept in Lupus Nephritis

Vera: Biotech With 3 Mid-Stage Programs With Potential For Success

Vera Therapeutics: Surprising Pivot To A Kidney Disease Drug Looks Like A Long Shot

High number of new directors

Vera Therapeutics Announces Acquisition of Monoclonal Antibody From Pfizer to Treat BK Virus in Transplant Patients

We Think Vera Therapeutics (NASDAQ:VERA) Can Afford To Drive Business Growth

Vera Therapeutics soars 16% on three new favorable view from analysts

Independent Chairman of the Board recently bought US$215k worth of stock

Vera Therapeutics, Inc. has completed an IPO in the amount of $47.85 million.

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane